MarketLens
Sign Up

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

5 months ago
SHARE THIS ON:

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 day ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

Legend Biotech (NASDAQ: LEGN) scheduled an investor conference call for 8:00 a.m. to discuss third quarter 2026 results. The notice gives no figures or guidance, so the call itself is the next catalys...
Stock News•1 months ago

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech reported CARVYKTI data showing 50% of RRMM patients remained progression-free and alive five years after a single infusion, with a 69.2% five-year overall survival rate. The results add...
Stock News•3 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates